150 related articles for article (PubMed ID: 30702869)
1. Peptide-Aptamer Coassembly Nanocarrier for Cancer Therapy.
Ma Y; Li W; Zhou Z; Qin X; Wang D; Gao Y; Yu Z; Yin F; Li Z
Bioconjug Chem; 2019 Mar; 30(3):536-540. PubMed ID: 30702869
[TBL] [Abstract][Full Text] [Related]
2. Aptamer-functionalized hybrid nanoparticle for the treatment of breast cancer.
Powell D; Chandra S; Dodson K; Shaheen F; Wiltz K; Ireland S; Syed M; Dash S; Wiese T; Mandal T; Kundu A
Eur J Pharm Biopharm; 2017 May; 114():108-118. PubMed ID: 28131717
[TBL] [Abstract][Full Text] [Related]
3. Multifunctional Nanodelivery Platform for Maximizing Nucleic Acids Combination Therapy.
Lee SK; Law B; Tung CH
Methods Mol Biol; 2020; 2115():79-90. PubMed ID: 32006395
[TBL] [Abstract][Full Text] [Related]
4. siRNA-aptamer chimeras on nanoparticles: preserving targeting functionality for effective gene silencing.
Bagalkot V; Gao X
ACS Nano; 2011 Oct; 5(10):8131-9. PubMed ID: 21936502
[TBL] [Abstract][Full Text] [Related]
5. Multivalent comb-type aptamer-siRNA conjugates for efficient and selective intracellular delivery.
Yoo H; Jung H; Kim SA; Mok H
Chem Commun (Camb); 2014 Jun; 50(51):6765-7. PubMed ID: 24830507
[TBL] [Abstract][Full Text] [Related]
6. Assessment of In Vivo siRNA Delivery in Cancer Mouse Models.
Hatakeyama H; Wu SY; Mangala LS; Lopez-Berestein G; Sood AK
Methods Mol Biol; 2016; 1402():189-197. PubMed ID: 26721492
[TBL] [Abstract][Full Text] [Related]
7. Preparation and characterization of novel albumin-sericin nanoparticles as siRNA delivery vehicle for laryngeal cancer treatment.
Yalcin E; Kara G; Celik E; Pinarli FA; Saylam G; Sucularli C; Ozturk S; Yilmaz E; Bayir O; Korkmaz MH; Denkbas EB
Prep Biochem Biotechnol; 2019; 49(7):659-670. PubMed ID: 31066619
[TBL] [Abstract][Full Text] [Related]
8. Efficient systemic delivery of siRNA by using high-density lipoprotein-mimicking peptide lipid nanoparticles.
Lin Q; Chen J; Jin H; Ng KK; Yang M; Cao W; Ding L; Zhang Z; Zheng G
Nanomedicine (Lond); 2012 Dec; 7(12):1813-25. PubMed ID: 22830501
[TBL] [Abstract][Full Text] [Related]
9. Ultra-pH-Responsive and Tumor-Penetrating Nanoplatform for Targeted siRNA Delivery with Robust Anti-Cancer Efficacy.
Xu X; Wu J; Liu Y; Yu M; Zhao L; Zhu X; Bhasin S; Li Q; Ha E; Shi J; Farokhzad OC
Angew Chem Int Ed Engl; 2016 Jun; 55(25):7091-7094. PubMed ID: 27140428
[TBL] [Abstract][Full Text] [Related]
10. Smart ligand: aptamer-mediated targeted delivery of chemotherapeutic drugs and siRNA for cancer therapy.
Li X; Zhao Q; Qiu L
J Control Release; 2013 Oct; 171(2):152-62. PubMed ID: 23777885
[TBL] [Abstract][Full Text] [Related]
11. Zwitterionic Nanocarrier Surface Chemistry Improves siRNA Tumor Delivery and Silencing Activity Relative to Polyethylene Glycol.
Jackson MA; Werfel TA; Curvino EJ; Yu F; Kavanaugh TE; Sarett SM; Dockery MD; Kilchrist KV; Jackson AN; Giorgio TD; Duvall CL
ACS Nano; 2017 Jun; 11(6):5680-5696. PubMed ID: 28548843
[TBL] [Abstract][Full Text] [Related]
12. Systemic Delivery of Anti-miRNA for Suppression of Triple Negative Breast Cancer Utilizing RNA Nanotechnology.
Shu D; Li H; Shu Y; Xiong G; Carson WE; Haque F; Xu R; Guo P
ACS Nano; 2015 Oct; 9(10):9731-40. PubMed ID: 26387848
[TBL] [Abstract][Full Text] [Related]
13. The application of aptamers in cancer research: an up-to-date review.
Hu M; Zhang K
Future Oncol; 2013 Mar; 9(3):369-76. PubMed ID: 23469972
[TBL] [Abstract][Full Text] [Related]
14. Strategies for siRNA navigation to desired cells.
Sioud M
Methods Mol Biol; 2015; 1218():201-16. PubMed ID: 25319653
[TBL] [Abstract][Full Text] [Related]
15. Aptamer delivery of siRNA, radiopharmaceutics and chemotherapy agents in cancer.
de Almeida CEB; Alves LN; Rocha HF; Cabral-Neto JB; Missailidis S
Int J Pharm; 2017 Jun; 525(2):334-342. PubMed ID: 28373101
[TBL] [Abstract][Full Text] [Related]
16. Budding Alliance of Nanotechnology in RNA Interference Therapeutics.
Kumawat A; Dapse P; Kumar N; Mishra DK; Maheshwari R; Bhattacharya P; Tekade RK
Curr Pharm Des; 2018; 24(23):2632-2643. PubMed ID: 30084328
[TBL] [Abstract][Full Text] [Related]
17. Ultrasound-mediated nanobubble destruction (UMND) facilitates the delivery of A10-3.2 aptamer targeted and siRNA-loaded cationic nanobubbles for therapy of prostate cancer.
Wu M; Zhao H; Guo L; Wang Y; Song J; Zhao X; Li C; Hao L; Wang D; Tang J
Drug Deliv; 2018 Nov; 25(1):226-240. PubMed ID: 29313393
[TBL] [Abstract][Full Text] [Related]
18. Nanoparticle-siRNA: a potential strategy for ovarian cancer therapy?
Aghamiri S; Mehrjardi KF; Shabani S; Keshavarz-Fathi M; Kargar S; Rezaei N
Nanomedicine (Lond); 2019 Aug; 14(15):2083-2100. PubMed ID: 31368405
[TBL] [Abstract][Full Text] [Related]
19. Co-Delivery of Doxorubicin and Survivin shRNA-Expressing Plasmid Via Microenvironment-Responsive Dendritic Mesoporous Silica Nanoparticles for Synergistic Cancer Therapy.
Li Z; Zhang L; Tang C; Yin C
Pharm Res; 2017 Dec; 34(12):2829-2841. PubMed ID: 28948461
[TBL] [Abstract][Full Text] [Related]
20. Nanoparticle orientation to control RNA loading and ligand display on extracellular vesicles for cancer regression.
Pi F; Binzel DW; Lee TJ; Li Z; Sun M; Rychahou P; Li H; Haque F; Wang S; Croce CM; Guo B; Evers BM; Guo P
Nat Nanotechnol; 2018 Jan; 13(1):82-89. PubMed ID: 29230043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
